Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 119

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 119
---
 18 months in an amount of approximately $10.2 million, of which approximately $1.3 million was allocated to us and for the
additional 18 months was approved an amount of approximately $15.4 million, of which approximately $1.9 million was allocated to us. Participation
in the IIA-sponsored consortium programs as described above does not obligate us to pay royalties to the IIA; however, the know-how developed
in such consortium programs is subject to the provisions and restrictions under the Innovation Law.

In March 2020 and March 2021, Lavie Bio obtained an IIA
approval to receive a grant for its third and fourth year programs, respectively, for bio fungicides for mildew in fruit and vegetables.
The total approved budgets for each of the third and fourth year programs were NIS 3.9 million (approximately $1.1 million for the
third year and approximately $1.2 million for the fourth year). In addition, during October 2022 Lavie Bio obtained an IIA approval to
receive a grant for the development of bio fungicide against soil diseases, seed rot, root and stem rot. The total approved budget was
approximately NIS 1.9 million (approximately $0.6 million).

In July 2022, Canonic received the Israeli Ministry of Economy
approval to be included in “ Smart money” grants program for marketing operations in Germany. The maximum grant amount from
this program is approximately $85 thousand. Canonic undertook to pay royalties of 3% of yearly revenues above approximately $284 thousand
derived from the operation in Germany, up to 100% of the grants received. As of December 31, 2024, Canonic received approximately $42
thousand for marketing expenses in Germany. Since Canonic has ceased its activities during the first half of 2024 and no economic benefits
are expected from the marketing operations in Germany, the grant receipts were recognized as a reduction of the related marketing expenses
during 2024.

In February 2024, Lavie Bio received the Israeli Ministry of Economy
approval to be included in the “ Smart money” grant program for initial exporting in Canada. The maximum grant amount from
this program is approximately $83 thousand. Lavie Bio undertook to pay royalties of 3% of yearly revenues above approximately $276 thousand
derived from the operation in Canada, up to 100% of the grants received (linked to The Consumer Price Index) and can choose